Pharmabiz17h
US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome
US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome: Marseille, France Tuesday, February 18, 2025, 12:00 Hrs ...
Innate’s lacutamab gains FDA breakthrough therapy designation
Innate Pharma has secured US Food and Drug Administration (FDA) breakthrough therapy designation for lacutamab to treat ...
Le Lézard1d
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ...
Oncology Nurse Advisor5d
CD70-Directed CAR-T Therapy Shows Promise in T-Cell Lymphoma
Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.
Medscape22d
Treatment of Cutaneous T-Cell Lymphoma/Mycosis Fungoides
The cause of mycosis fungoides is unknown and, with the possible exception of very early stage disease, no cure is available. Fortunately, patients with MF have a number of therapeutic options and ...
Canada26d
Government of Canada signs bilateral agreement with Ontario for Drugs for Rare Diseases
The first step in this bilateral agreement will be to deliver funding to the province to provide access to five drugs under the National Strategy for Rare Diseases: Poteligeo, for the treatment of ...
Ontario News26d
Ontario Connecting More People to Treatment for Rare Diseases
TORONTO – The Ontario government is connecting more people to the care they need by ensuring Ontarians, of all ages, living with rare diseases have faster and easier access to new and emerging ...
CNN27d
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...
Pharmaceutical Technology29d
Tulmimetostat by MorphoSys for Mycosis Fungoides: Likelihood of Approval
Tulmimetostat is under development for the treatment of the solid tumors including metastatic castration-resistant prostate cancer, mycosis fungoides, Sezary syndrome, peripheral T-cell lymphoma (PTCL ...
Pharmaceutical Technology29d
Tulmimetostat by MorphoSys for Peritoneal Cancer: Likelihood of Approval
Tulmimetostat is under development for the treatment of the solid tumors including metastatic castration-resistant prostate cancer, mycosis fungoides, Sezary syndrome, peripheral T-cell lymphoma (PTCL ...
Medical Xpress1mon
Investigating new treatments for rare skin lymphomas
including the most common subtypes mycosis fungoides and Sézary syndrome, were given DD-cxdl for five consecutive days every 21 days. Roughly 36% of patients responded to the treatment ...